Description: AFFINITY arterial blood filters are sterile, non-pyrogenic devices for single use and are designed to filter micro-symbols of the largest size circuit in microns specified, for periods of up to 6 hours during cardiopulmonary bypass surgery. Use: these filters are indicated for use in all cardiopulmonary bypass procedures for the removal of particles and gaseous micro piston. The filters are single-use, sterile, non-pyrogenic devices designed to filter micro-plots larger than the specified micron size from the circuit of periods of up to six hours during cardiopulmonary bypass surgery. AFFINITY351 / cb351 arterial filter (38μ, 351 / cb351 arterial blood filter (20μ arterial blood filter) AFFFITY arterial blood filters are sterile, non-pyrogenic devices for single use and are designed to filter microcircuits of the circuit greater than the specified micron size, for periods of up to 6 hours during cardiopulmonary bypass surgery AFFINITY arterial blood filters carmeda (cb351 and cb 353) are coated with an impermeable bioactive surface (heparin), which provides blood contact surfaces resistant to thrombus formation TRILLIUM AFFINITRY NT 541t: the membrane oxygenator with integrated CVR AFFINITY NT (plasma-resistant defibra oxygenator (PRF) with bioactive surface TRILLIUM is designed to be used in an extracorporeal perfusion circuit to collect venous blood and blood-pitched cardiotomy, to heat or cool the blood, and to oxygenate and eliminate the dioxide blood carbon during systemic cardiopulmonary bypass procedures for up to 6 hours.
“If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.